REG - GSK PLC - Jemperli trial meets overall survival endpoint

GSKAnnouncement

30/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231030:nRSd6240Ra&default-theme=true

RNS Number : 6240R  GSK PLC  30 October 2023

Issued: 30 October 2023, London UK

 

Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets
endpoint of overall survival in patients with primary advanced or recurrent
endometrial cancer

 

·   Statistically significant and clinically meaningful overall survival
benefit observed in the overall population in the trial

 

·   Dostarlimab plus chemotherapy is the only immuno-oncology combination
regimen to show an overall survival benefit in this patient population

 

 

 

GSK plc (LSE/NYSE: GSK) today announced positive headline results from a
planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial
investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy
(carboplatin and paclitaxel), followed by dostarlimab as a single agent,
compared to placebo plus chemotherapy followed by placebo in adult patients
with primary advanced or recurrent endometrial cancer. The trial met its
primary endpoint of overall survival (OS), demonstrating a statistically
significant and clinically meaningful benefit in the overall patient
population.

 

A clinically meaningful OS benefit was observed in both prespecified
subpopulations in the trial: mismatch repair deficient (dMMR)/microsatellite
instability-high (MSI-H) and mismatch repair proficient (MMRp)/microsatellite
stable (MSS) patient subgroups. OS is one of two primary endpoints in the RUBY
Part 1 trial. Previously, the trial met its other primary endpoint of
progression-free survival (PFS), demonstrating a 72% and 36% reduction in the
risk of disease progression or death observed in the dMMR/MSI-H population
(HR: 0.28 [95% CI: 0.16-0.50]) and overall patient population (HR: 0.64 [95%
CI: 0.51-0.80]), respectively 1  (#_edn1) .

 

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK,
said: "With today's headline results from Part 1 of the phase III RUBY trial,
dostarlimab plus chemotherapy has become the only immuno-therapy combination
to show a survival benefit in this broader patient population in this
treatment setting. We look forward to sharing detailed results of this
analysis with regulatory authorities and the larger scientific community."

 

Full results from this latest analysis from the trial will be published in a
medical journal and presented at an upcoming scientific meeting.

The safety and tolerability profile of dostarlimab plus carboplatin and
paclitaxel was generally consistent with the known safety profiles of the
individual agents. The most common treatment-emergent adverse events (≥ 25%)
in patients receiving dostarlimab plus chemotherapy were nausea, alopecia,
fatigue, peripheral neuropathy, anemia, arthralgia, constipation, diarrhoea
and myalgia.

 

Currently, Jemperli has regulatory approvals in a certain subset of patients
with endometrial cancer based on the previously reported positive results for
the primary endpoint of progression-free survival in Part 1 of the RUBY trial.
In July 2023, Jemperli received FDA approval in combination with carboplatin
and paclitaxel, followed by Jemperli as a single agent for the treatment of
adult patients with primary advanced or recurrent endometrial cancer that is
mismatch repair deficient (dMMR), as determined by an FDA-approved test, or
microsatellite instability-high (MSI-H). Jemperli was also approved in the
United Kingdom in October 2023 in combination with platinum-containing
chemotherapy for the treatment of adult patients with dMMR/MSI-H primary
advanced or recurrent endometrial cancer and who are candidates for systemic
therapy. The application remains under review in the European Union (EU),
Australia, Canada, Switzerland and Singapore.

 

About endometrial cancer

Endometrial cancer is found in the inner lining of the uterus, known as the
endometrium. Endometrial cancer is the most common gynaecologic cancer in
developed countries, with approximately 417,000 new cases reported each year
worldwide([ 2  (#_edn2) )(]), and incidence rates are expected to rise by
almost 40% between 2020 and 2040.([ 3  (#_edn3) ][ 4  (#_edn4) ])
Approximately 15-20% of patients with endometrial cancer will be diagnosed
with advanced disease at the time of diagnosis.([ 5  (#_edn5) ])

 

About RUBY
RUBY is a two-part global, randomised, double-blind, multicentre phase III
trial of patients with primary advanced or recurrent endometrial cancer. Part
1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by
dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo.
Part 2 is evaluating dostarlimab plus carboplatin-paclitaxel followed by
dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed
by placebo.

 

The dual-primary endpoints in Part 1 are investigator-assessed PFS based on
the Response Evaluation Criteria in Solid Tumours v1.1 and OS. The statistical
analysis plan included pre-specified analyses of PFS in the dMMR/MSI-H and ITT
populations and OS in the overall population. Pre-specified exploratory
analyses of PFS and OS in the MMRp/MSS population and OS in the dMMR/MSI-H
populations were also performed. RUBY Part 1 included a broad population,
including histologies often excluded from clinical trials and had
approximately 10% of patients with carcinosarcoma and 20% with serous
carcinoma. In Part 2, the primary endpoint is investigator-assessed PFS.
Secondary endpoints in Part 1 and Part 2 include PFS per blinded independent
central review, overall response rate, duration of response, disease control
rate, patient-reported outcomes, and safety and tolerability.

About Jemperli (dostarlimab)

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds
to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1
and PD-L2.([ 6  (#_edn6) ])

 

In the US, Jemperli is indicated in combination with carboplatin and
paclitaxel, followed by Jemperli as a single agent for the treatment of adult
patients with primary advanced or recurrent endometrial cancer that is
mismatch repair deficient (dMMR), as determined by an FDA-approved test, or
microsatellite instability-high (MSI-H), and as a single agent for adult
patients with mismatch repair-deficient (dMMR) recurrent or advanced
endometrial cancer, as determined by a US FDA-approved test, that has
progressed on or following a prior platinum-containing regimen in any setting
and are not candidates for curative surgery or radiation. The sBLA supporting
the indication in combination with carboplatin and paclitaxel received
Breakthrough Therapy designation from the FDA. Jemperli is also indicated in
the US for patients with dMMR recurrent or advanced solid tumours, as
determined by a US FDA-approved test, that have progressed on or following
prior treatment and who have no satisfactory alternative treatment options.
The latter indication is approved in the US under accelerated approval based
on tumour response rate and durability of response. Continued approval for
this indication in solid tumours may be contingent upon verification and
description of clinical benefit in a confirmatory trial(s).

 

Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc.,
under a collaboration and exclusive license agreement signed in March 2014.
The collaboration has resulted in three monospecific antibody therapies that
have progressed into the clinic. These are: Jemperli (GSK4057190), a PD-1
antagonist; cobolimab, (GSK4069889), a TIM-3 antagonist; and GSK4074386, a
LAG-3 antagonist. GSK is responsible for the ongoing research, development,
commercialisation, and manufacturing of each of these medicines under the
agreement.

 

Important Information for Jemperli in the EU

 

Indication 

Jemperli is indicated as monotherapy for treating adult patients with mismatch
repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or
advanced endometrial cancer that has progressed on or following prior
treatment with a platinum-containing regimen.

 

Refer to the Jemperli EMA Reference Information for a full list of adverse
events and the complete important safety information in the EU here:
https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
(https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli) .

 

GSK in oncology

GSK is committed to maximising patient survival through transformational
medicines, with a current focus on breakthroughs in immuno-oncology and
tumor-cell targeting therapies, and development in haematologic malignancies,
gynaecologic cancers and other solid tumours.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502    (London)
                      Dan Smith          +44 (0) 20 8047 5502    (London)
                      Kathleen Quinn     +1 202 603 5003         (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595         (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834     (London)
                      James Dodwell      +44 (0) 20 8047 2406    (London)
                      Mick Readey        +44 (0) 7990 339653     (London)
                      Josh Williams      +44 (0) 7385 415719     (London)
                      Camilla Campbell   +44 (0) 7803 050238     (London)
                      Steph Mountifield  +44 (0) 7796 707505     (London)
                      Jeff McLaughlin    +1 215 751 7002         (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855         (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q2 Results for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

References

 1 Mirza M, et al. N Engl J Med 2023; 388:2145-2158; DOI:
10.1056/NEJMoa2216334

 2  (#_ednref2) Faizan U, Muppidi V. Uterine Cancer. [Updated 2022 Sep 5]. In:
StatPearls  Internet . Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
Available at: https://www.ncbi.nlm.nih.gov/books/NBK562313/.

 3  (#_ednref3) Braun MM, et al. Am Fam Physician. 2016;93(6):468-474.

 4  (#_ednref4) International Research on Cancer. Global Cancer Observatory.
Cancer Tomorrow. https://gco.iarc.fr/tomorrow/en/dataviz/. Accessed 13 July
2022.

 5  (#_ednref5) Kantar Health, Cust Study (2018).

 6  (#_ednref6) Laken H, Kehry M, Mcneeley P, et al. Identification and
characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody.
European Journal of Cancer. 2016;69,S102. doi:10.1016/s0959-8049(16)32902-1.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFVIIVLAFIV